Background: Nowadays, safety of a drug is a major challenge than its efficacy. As the demand for Ayurvedic drugs is increasing day by day, the reporting of safety is essential.
BACKGROUND
Established researchers and people, in general, have turned out to be progressively mindful of and legitimately worried about the wellbeing of women, and there is ensuing expanding interest to assess the potential health risk factors of women. In India, the life expectancy of females is lacking, which further indicates the absence of orderly issues in the women's health care. 1 Women and men in India have nearly the same life expectancy at birth, whereas as age advances better health status and life expectancy are not seen in females, which reflects the poor health of women in India. Due to high mortality rates amid the adolescent and reproductive years, care for women's health is a pivotal issue. 2 A woman's reproductive organs are constantly showing signs of change. The anatomical, physiological, and emotional changes occur drastically in the body of women at different stages right from the pubescence stage to menopause. In Ayurveda, Prasutitantra, which deals with the Obstetrics and Gynecology section, describes the major health issues in a woman's reproductive system as Yoni vyaapad, which are health problems related to menstruation and the female genital organs, and they are 20 in number. 3 The rest of the problems related to a woman's reproductive system, such as complications occurring in pregnancy, during labor, after delivery, and during lactation have been described separately.
The awareness of the benefits in using Ayurvedic medicines is growing in India and also across the globe. Therefore, with the increasing use of Ayurvedic medicines, the concerns of safety are being raised accordingly. 4 It is highly accepted that clinical trials are the most ideal approach to assess the efficacy of any treatment. It has been observed that although emphasis has been given on the reporting of the clinical efficacy of Ayurvedic drugs, positive outcomes like clinical safety, improvement in quality-of-life, easy availability of medicines, and lower costs have been underreported.
Although safety is an intrinsic strength of the Ayurvedic system of medicine, a better safety/tolerability assessment framework is constantly required to measure the extent of safe use of these medicines. Ayurveda has always stressed upon or focused on safe treatment, which includes alleviation of a disease condition and not stimulating occurrence any other disease due to the treatment. 5 Any new intervention/drug, when introduced, is then expected to match the efficacy of the standard intervention/drug or existing drugs. In some instances, it may happen that the new intervention/drug may demonstrate additional advantages too i.e. convenience in use, cost effectiveness, or more safety than the existing drug. There needs to be a combined and integrative approach when evaluating the efficacy and safety of a drug, and due importance should be assigned to safety.
From the literature review, it has been revealed that although a number of clinical studies with classical Ayurvedic formulations have already been conducted from time-to-time, and reports on their efficacy by researchers have been performed, establishing the clinical safety of the medicines is very negligible. It may be assumed that as the drugs have been in use for a long period and they are mostly plant-based, they are safe to use without any adverse reaction or due importance may not be given to this issue.
Considering the importance of reporting the safety of Ayurvedic formulations, the aim of this manuscript is to report the clinical safety of some classical Ayurvedic formulations, which were trialed in 3 clinical trials on women's health. This study aimed to assess their safety along with the efficacy at research centers located at different geographical regions of the country.
OBJECTIVE
To report the clinical safety of Ayurvedic formulations, viz., Rajahpravartini vati, 6 Kanchanara Guggulu, 7 
Varunadi
Kashaya, 8 Ashokarishta, 9 Ashvagandha Churna, 10 and Pravala Pishti, 11 which were studied in 3 clinical trials on women's health.
MATERIALS AND METHODS
The analyzed data of 3 clinical studies (single arm study), with the above-mentioned 6 clinical Ayurvedic formulations conducted at different centers and periods under the intramural research (IMR) program of the CCRAS, were collected from the data repository of the organization. The study protocol and related documents of all the studies were reviewed and approved by the Institutional Ethics Committee of each participating center. The studies were conducted in accordance with the Schedule-Y of Drugs and Cosmetics Act, India, amended in 2005 and the Indian Council of Medical Research ethical guidelines for biomedical research on human participants, adopted from the World Medical Association (WMA)-Declaration of Helsinki. The participants of all the studies were informed about the study procedures. The eligibility criteria were checked precisely and informed consent forms were also signed by the participants before their enrolment in the study. All three studies were also registered in the Clinical Trial Registry of India (CTRI). The efficacy has already been reported for two studies, whereas efficacy data of one study are under publication. 12, 13 The name of the study, study period, and CTRI number are presented in Table 1 .
Study Participants

Inclusion and Exclusion Criteria
Study 1: Women aged between 16 and 35 years suffering from painful menstruation for at least three consecutive regular menstrual cycles (21-35 days) and having normal bleeding were included in the study. Patients of secondary dysmenorrhea, abnormal reproductive system, pelvic inflammatory disease, or any serious systemic disorders likely to influence the menstrual cycle, history of malignancy, hypo and hyperthyroidism, diabetes mellitus, hypertension, women using intrauterine device/ oral contraceptive pills, and participating in any other interventional study were excluded from the study. Pregnant and lactating women were also excluded. Study 2: Women aged between 40 and 55 years, amenorrhea for ≥12 months, Kupperman menopausal index score ≥15, follicle-stimulating hormone ≥20 IU/L, and thickness of endometrium ≤5 mm, and those who agreed to participate were included in the study.
Exclusion criteria included history of surgical menopause; evidence of malignancy; established cases of mental illness, diabetes mellitus, hypertension, rheumatoid arthritis, coronary heart disease, hepatic disorder, chronic obstructive pulmonary disease, and hypothyroidism; the women on prolonged (>6 weeks) medication with corticosteroids, antidepressants, anticholinergics, or any other drugs that might have an influence on the outcome of the study; alcoholics and/or drug abusers, and who have participated in any other clinical trial in the past 6 months of screening.
Study 3: Women aged between 18 and 40 years with PCOS, as defined by Rotterdam 2003 criteria, having hyperandrogenism clinically (hirsutism)/or biochemically (elevated serum testosterone concentrations), hnovulation/or oligomenorrhea (cycles of 35 days or longer), or amenorrhea (no menses in the last 6 months) after negative screening pregnancy test and polycystic ovary (more than 10 follicles in a ovary/or one cyst more than 10 mm in size), who were able to comply with the requirements of the study and willing to provide signed informed consent were included in the study.
Women who were younger than 18 years or older than 40 years; having history of primary amenorrhea and secondary amenorrhea due to lactation; who were pregnant/ or have planned pregnancy during the treatment period; women having any organic reproductive system abnormalities (diagnosed clinically and radiologically), pelvic inflammatory disease, hydrosalpinx, endometriosis, adenomyosis, fibroid uterus, and carcinoma of reproductive organ; subjects with metabolic and endocrinal disorders like diabetes mellitus, chronic liver disease, renal disorder, high blood pressure, hypo and hyperthyroidism; subjects having history of current or previous (within the last 3 months) use of oral contraceptives, glucocorticoids, antiandrogens, ovulation-induction agents, antidiabetic and antiobesity drugs, or other hormonal drugs; subjects who had ingested any investigational drug within 4 weeks prior to the recruitment in the study, and subjects who had no uterine bleeding in the progesterone challenge test were excluded from the study.
Details of Study Interventions in These Three Clinical Trials
Totally, six classical Ayurvedic formulations were studied for their safety and efficacy in the said clinical trials. All the formulations were procured from the GMP-certified manufacturing companies following the standard operative procedures for preparation and standards laid down in the Ayurvedic Pharmacopoeia of India (API). The ingredients and textual references of each formulation are presented in Table 2 . The duration of drug administration, dose, dosage form, and vehicle are presented in Table 3 . 
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Study Procedures
At screening visit, subject's demographic profile, medical history, family history, history particularly related to gynecological disorders, menstrual history, Prakriti (body constitution), and vital parameters were recorded. At each visit, i.e., baseline, 30th, 60th, 90th day, etc. study medications were dispensed and clinical assessments were performed. Safety laboratory assessments were done at the beginning and at the end of the intervention period. Subject's compliance was monitored by keeping up a regular follow-up by personal contact or telephonic/ electronic communication. The investigators checked the medicine packaging for its compliance at each visit. On each follow-up visit, subject's general and systemic examinations were also carried out. The ADRs (e.g., headache, dizziness, nausea, vomiting, etc) or adverse events, if any, reported during the treatment period were also recorded during each follow-up as per the protocol of the studies.
Safety Assessment
The clinical safety of the participants was assessed through safety laboratory parameters like blood urea, serum creatinine, serum alkaline phosphatase, aspartate aminotransferase , serum alanine aminotransferase, and total bilirubin. These were assessed at baseline and at the end of the intervention period in each study.
All the subjects were specifically questioned as per a predetermined list of common symptoms that may have occurred during treatment period (anorexia, nausea, vomiting, diarrhea, constipation, dysuria, skin rash, giddiness, oral mucous ulcers, dyspepsia, and abdominal discomfort and pain) based on the experiences in clinical practice and previous trials. Participants were also encouraged to voluntarily report information that they considered to be adverse events or a side effect.
STATISTICAL ANALYSIS
The clinical safety parameters were analyzed according to the intention-to-treat analysis. Missing values were imputed by the last-observation carried-forward method. Statistical analysis was performed using Statistical Packages for Social Sciences version 15 effects of outcome measures were done by using repeated measures analysis of variance.
RESULTS
In the study 1, 2, and 3, the data of 359, 115, and 60 subjects have been analyzed by imputation for intension-to-treat analysis for safety and efficacy evaluation. The baseline values of different variables viz. age, marital status, and other demographic profiles, etc., of these subjects are given in Table 4 , and data on vital parameters and body mass index (BMI) are presented in Table 5 .
Effect of the Trial Drugs on Safety Parameters
As the trial drugs were administered in combination for 3 months continuously and also for 6 months, for assessment of their clinical safety, laboratory safety parameters, i.e., renal and liver functions test, were carried out at baseline and at the end of the treatment in all the studies. From the data, it is observed that though some variations are found in the data (mean ± SD) of both ends, all were in the normal range and no statistically significant changes were observed. This finding helps establish the safety of the drug for human use. The details are presented in Tables 6, 7 , and 8. Further, it is also observed that none of the study subjects withdrew due to any adverse event or drug-related toxicity.
DISCUSSION
The primary objective of the manuscript is to evaluate the safety of 6 Ayurvedic formulations trialed in 3 different is being found in various Ayurvedic texts. Though the term ADR is not found, the concept of the same and safety issues are profoundly mentioned at full length in the Ayurvedic texts. The Ayurveda system of medicine, since its inception, has given utmost importance to the safety and benefit of the patient during the entire period of the management of diseases, and includes raw drug selection, raw drug collection, the processing methods, and the administration of drug in appropriately diagnosed patient. The ADR can be minimized if one uses medicines of good quality and perform assessments by Dashavida pareeksha (ten-fold examination of diseased person), 16 viz., Prakriti (body constitution), Vaya (Age), vikruti (any pathological condition), satmya (tolerance), vyayamshakti (capacity of exercise), Saara (tissue quality), samhanana (physical proportion), and bala (strength); by Trividha praeeksha 17 (three-fold examination of diseased person), Chaturvidha pareeksha (four-fold examination of patients), 18 Shadvidha preeksha 19 (six-fold examination), and Ashtavidh pareeksha (eight-fold examination). 20 As mentioned in texts, if the drug administered is stronger than the disease, then it produces another disease after pacifying the present one, and if the strength is lower, then the drug becomes ineffective stating importance of administration of drug in appropriate strength. 21 Ayurvedic formulations are mainly of herbs and herbo-mineral/metal compositions. Ayurveda states that every Aushadha (single/compound formulations), be it herbal or herbo-mineral/metal, if, not used judiciously may cause harm to the body, which may be mild-to-severe or unpredictable. There are many studies reporting on the drug interactions also, i.e., bleeding tendency after intake of phenproprocoumon 22 Rajahpravartini Vati having kasisa (purified green vitriol) and Kanchanar Guggulu were manufactured after purification following the methods mentioned in texts for kasisa 29 and guggulu. 30 All the ingredients had been taken as per API standards and the finished products were also manufactured following the standards laid in the API at GMP-certified pharmaceutical companies. As shown in Table 2 , the said formulations were successfully administered in different centers across the country covering different geographical regions but no adverse effects/reactions were reported. Thus, it proves the safety profile of the formulations administered. To summarize this, the Ayurveda system of medicines supports the fact of "safe administration" of medicine stating that "even a strong poison can become an excellent medicine if administered properly and on the contrary even the most useful drug can act like a poison if handled carelessly."
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CONCLUSION
The Ayurvedic formulations, viz., Rajahpravartini vati, Kanchanara Guggulu, Varunadi Kashaya, Ashokarishta, Ashvagandha Churna, and Pravala Pishti, are found clinically safe as no ADRs and no significant changes in biochemical parameters of liver and kidney function were reported during the treatment period in all three studies.
The results of the present studies support the notion that if any Ayurvedic formulation has been manufactured as per GMP following the standard operative procedures laid down in the classics and administered at the recommended dose and duration, it is safe for human use.
